- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Aclarion: Interview With CEO Brent Ness About The Digital Health Company Addressing A Worldwide Epidemic | 2 | pulse2.com | ||
| Mi | Aclarion, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Aclarion appoints first UK commercial director as insurance coverage expands | 1 | Investing.com | ||
| 05.11. | Aclarion, Inc.: Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion | 2 | GlobeNewswire (USA) | ||
| 22.10. | Aclarion, Inc.: Aclarion Wins "Rising Star" at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH | 1 | GlobeNewswire (USA) | ||
| 14.10. | Aclarion reports 89% increase in Nociscan scan volumes in Q3 | 1 | Investing.com | ||
| 14.10. | Aclarion, Inc.: Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst | 141 | GlobeNewswire (Europe) | Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89%... ► Artikel lesen | |
| 14.10. | Aclarion, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| ACLARION Aktie jetzt für 0€ handeln | |||||
| 13.10. | Aclarion Stock Rises 32% After Global Pain Conference Presentation | 1 | RTTNews | ||
| 13.10. | Teilnahme an Fachkonferenz beflügelt Aclarion-Aktie | 1 | Investing.com Deutsch | ||
| 13.10. | Aclarion stock soars after participation in international pain meeting | 2 | Investing.com | ||
| 13.10. | XFRA MISTRADE ANTRAG IN ISIN US6551874091 WURDE ABGELEHNT | 205 | Xetra Newsboard | Der Mistrade-Antrag wurde abgelehnt. Folgende Geschaefte in der ISIN US6551874091, Wertpapier-Name: ACLARION NEW DL-,00001, werden nicht aufgehoben:Datum Zeit Volumen Preis13.10.2025 10:01:46 400 8,8 ► Artikel lesen | |
| 13.10. | XFRA MISTRADE ANTRAG IN ISIN US6551874091 WIRD GEPRUEFT | 176 | Xetra Newsboard | Fuer folgende Geschaefte in der ISIN US6551874091, Wertpapier-Name: ACLARION NEW DL-,00001, wird ein Mistrade-Antrag geprueft:Datum Zeit Volumen Preis13.10.2025 10:01:46 400 8.8Fair Value lt. Antragsteller:... ► Artikel lesen | |
| 09.10. | Aclarion to Present at the LD Micro Main Event XIX | 231 | Newsfile | Broomfield, Colorado--(Newsfile Corp. - October 9, 2025) - Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 07.10. | Aclarion, Inc.: Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH | 1 | GlobeNewswire (USA) | ||
| 01.10. | Aclarion, Inc.: Aclarion Presents at LSI Europe '25 Highlighting Nociscan Technology and Key Value Drivers | 2 | GlobeNewswire (USA) | ||
| 25.09. | Aclarion, Inc.: First Patients Enrolled at UHealth - University of Miami in Aclarion's Pivotal CLARITY Trial | 2 | GlobeNewswire (USA) | ||
| 19.09. | Aclarion stock price target raised to $22 from $20 by Ascendiant Capital | 2 | Investing.com | ||
| 03.09. | Aclarion, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.09. | Aclarion taps Greg Gould as CFO | 1 | Seeking Alpha |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 275,05 | -0,60 % | UnitedHealth: Trump teilt aus - droht weiteres Ungemach? | Die Euphorie bei UnitedHealth nach dem Einstieg von Warren Buffetts Beteiligungsgesellschaft Berkshire Hathaway und der etwas besseren Ergebnisprognose mit Blick auf das laufende Jahr nach dem Q3-Bericht... ► Artikel lesen | |
| INTUITIVE SURGICAL | 472,55 | +0,18 % | Intuitive Surgical Stock Is Up 31% Since October Lows After Powerful Earnings Turnaround | ||
| THERMO FISHER | 485,65 | -0,79 % | Thermo Fisher Gains 510(k) Clearance For EXENT System To Aid Multiple Myeloma Diagnosis | WASHINGTON (dpa-AFX) - Thermo Fisher Scientific Inc. (TMO) on Wednesday announced 510(k) clearance for its EXENT Analyzer and Immunoglobulin Isotypes (GAM) Assay, aimed at supporting faster... ► Artikel lesen | |
| ROKU | 83,18 | -0,48 % | Roku Unveils Black Friday And Cyber Monday Deals Starting November 20 | WASHINGTON (dpa-AFX) - Beginning November 20, Roku Inc (ROKU) will be offering significant holiday discounts on all of its TVs, streaming devices, and smart home goods. Customers can now purchase... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,712 | +4,86 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update | Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development programs for potential 2026-NDA enabling activities... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| CENTENE | 31,990 | -0,03 % | Jim Cramer Discusses Centene (CNC) & Medicaid | ||
| QUIDELORTHO | 18,500 | +1,09 % | QuidelOrtho Corporation: QuidelOrtho Reports Third Quarter 2025 Financial Results | ? Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ? ... ► Artikel lesen | |
| VERU | 2,450 | 0,00 % | Veru Inc.: Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress | --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update | BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated... ► Artikel lesen | |
| NANO-X IMAGING | 2,825 | 0,00 % | Nano-X Imaging Ltd: Nanox Partners with French Radiology Group Olympe Imagerie to Advance Clinical Validation in Europe | Olympe Imagerie to deploy Nanox.ARC at Paris-area Hospital Privé Jacques Cartier MASSY for lung cancer screening applications PETACH TIKVA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING... ► Artikel lesen | |
| FULGENT GENETICS | 24,800 | -0,80 % | Raymond James erhöht Kursziel für Fulgent Genetics nach starken Zahlen auf 36 US-Dollar | ||
| LANTHEUS | 45,700 | +0,88 % | Lantheus Holdings, Inc.: Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update | Recorded third quarter 2025 worldwide revenue of $384.0 million, GAAP fully diluted earnings per share of $0.41, adjusted fully diluted earnings per share of $1.27 and free cash flow of $94.7 millionSeparately... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 1,840 | -4,17 % | Oppenheimer lowers Perspective Therapeutics stock price target on competitive data | ||
| AMN HEALTHCARE SERVICES | 12,700 | 0,00 % | AMN Healthcare Services Inc: AMN Healthcare Announces Third Quarter 2025 Results | Quarterly revenue of $634 million and adjusted EBITDA of $58 million; GAAP income of $0.76/share and adjusted EPS of $0.39 DALLAS, Nov. 06, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE:... ► Artikel lesen |
Das Unternehmen ACLARION INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 5,100 Euro und damit +0,39 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACLARION INC finden Sie auf Wallstreet Online.